The Technology Behind Bluebird Bio

The video discusses Bluebird Bio's role in the biotech industry, focusing on gene therapy, cancer immunotherapy, and gene editing. It highlights the importance of Boston's ecosystem, including academia, innovation, and investors. The CEO, Nick Lashley, emphasizes the need for a global talent pool and the impact of immigration policies. The discussion also covers venture capital, public markets, and Bluebird's long-term vision, including deals with Novartis and GSK to advance gene therapy technologies.

What are the main platforms that Bluebird bio focuses on?

How does Bluebird bio differentiate its gene therapy from competitors?

What role does the Boston ecosystem play in the success of biotech companies like Bluebird?

What challenges does Bluebird bio face regarding talent acquisition?

How does Bluebird bio plan to evolve its business in relation to rare diseases?

What is the significance of the deals struck with Novartis and Glaxo Smith Kline?

In what ways does Bluebird bio aim to create products that make a difference for patients?